NASDAQ · MSLE
Satellos Bioscience Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MSLE: Nov 13, 2026
Satellos Bioscience Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.44. The reported EPS for the same quarter last year was $-0.36.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.44 | $-0.43 | $-0.44 | 2 |
| Dec 2026 | $-0.50 | $-0.40 | $-0.60 | 2 |
| Mar 2027 | $-0.43 | $-0.43 | $-0.43 | 1 |
| Jun 2027 | $-0.47 | $-0.47 | $-0.47 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat- RTTNews · Sep 30, 8:23 AM EDTSatellos Completes Enrollment In Phase 2 Forazapadin Trial For DMD(RTTNews) – On Wednesday, Satellos Bioscience (MSLE) said it has completed enrollment in BASECAMP, a Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy (DMD) in ambulatory boys aged 7 to 10 years.
- RTTNews · Sep 24, 7:29 AM EDTSatellos Gets FDA Clearance For Forazapadin In FSHD; Phase 2 Study Planned(RTTNews) – Satellos Bioscience Inc. (MSLE) announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug application for forazapadin for the treatment of facioscapulohumeral muscular dystrophy (FSHD), expanding development of the investigational
- RTTNews · Sep 9, 7:53 AM EDTSatellos Names Forazapadin As INN For Lead DMD Drug Candidate(RTTNews) – Satellos Bioscience Inc. (MSLE) announced that the World Health Organization has assigned the International Nonproprietary Name (INN) forazapadin to its lead drug candidate, previously known as SAT-3247.
- RTTNews · Jul 22, 11:09 PM EDTTop Biotech Gainers: ZCMD Surges 190%, LABT Advances On Nu-3 Progress, ARWR Hits The Targets(RTTNews) – Today's top gainers in the healthcare sector include Zhongchao, surging more than 190%; Lakewood-Amedex, advancing on positive antimicrobial drug progress; Arrowhead, delivering encouraging severe hypertriglyceridemia trial results; and LB Pharma, accelerating the LB-
- MarketBeat · Jul 10, 3:02 PM EDTSatellos Bioscience DMD Drug Shows Early Promise in 6-Month Study UpdateSatellos Bioscience (NASDAQ:MSLE) said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne muscular dystrophy, in a small cohort of adult participants. The company reported
- RTTNews · Jul 10, 12:10 PM EDTWeekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal(RTTNews) – This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech and pharmaceutical sectors.
- RTTNews · Jul 8, 11:30 AM EDTSatellos Releases Promising Interim Data From Phase 2 TRAILHEAD For SAT-3247 In DMD; Stock Up(RTTNews) – Satellos Biosciences Inc. (MSLE), a clinical-stage biotechnology company, on Wednesday reported six-month interim data from the Phase 2 TRAILHEAD study for SAT-3247 in treating Duchenne Muscular Dystrophy.
- RTTNews · Jun 29, 12:16 PM EDTSatellos' SAT-3247 Wins FDA Fast Track Status For Duchenne Muscular Dystrophy, Stock Up(RTTNews) – Satellos Bioscience Inc. (MSLE), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration has granted Fast Track Designation to SAT-3247 for the treatment of Duchenne Muscular Dystrophy, or DMD.
- RTTNews · Jun 29, 7:53 AM EDTSatellos Bioscience's Duchenne Drug SAT-3247 Wins FDA Fast Track Designation(RTTNews) – Monday, Satellos Bioscience Inc. (MSLE) announced that the U.S. Food and Drug Administration has granted Fast Track designation to SAT-3247 for the treatment of Duchenne muscular dystrophy.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Satellos Bioscience Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.